Healthcare -
Drug Manufacturers - Specialty & Generic - NASDAQ - CA
$ 1.24
-3.88 %
$ 258 M
Market Cap
-0.3
P/E
1. INTRINSIC VALUE
FINANCIALS
Balance Sheet
Canopy Growth Corporation
| Current Assets | 293 M |
| Cash & Short-Term Investments | 137 M |
| Receivables | 52.5 M |
| Other Current Assets | 103 M |
| Non-Current Assets | 620 M |
| Long-Term Investments | 179 M |
| PP&E | 292 M |
| Other Non-Current Assets | 149 M |
| Current Liabilities | 93.9 M |
| Accounts Payable | 25.9 M |
| Short-Term Debt | 20.7 M |
| Other Current Liabilities | 47.2 M |
| Non-Current Liabilities | 334 M |
| Long-Term Debt | 326 M |
| Other Non-Current Liabilities | 8.44 M |
EFFICIENCY
Earnings Waterfall
Canopy Growth Corporation
| Revenue | 267 M |
| Cost Of Revenue | 212 M |
| Gross Profit | 55 M |
| Operating Expenses | 121 M |
| Operating Income | -66 M |
| Other Expenses | 535 M |
| Net Income | -601 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Canopy Growth Corporation
| Net Income | -601 M |
| Depreciation & Amortization | 42.9 M |
| Capital Expenditures | -10.8 M |
| Stock-Based Compensation | -4.2 M |
| Change in Working Capital | -41.1 M |
| Others | 428 M |
| Free Cash Flow | -177 M |
Wall Street Analysts Price Targets
Canopy Growth Corporation
Wall Street analysts predict an average 1-year price target for CGC of $17.7 , with forecasts ranging from
a
low of
$8 to a high of $35 .
CGC Lowest Price Target
Wall Street Target
8 USD
545.16%
CGC Average Price Target
Wall Street Target
17.7 USD
1325.40%
CGC Highest Price Target
Wall Street Target
35 USD
2722.58%
4. DIVIDEND
ANALYSIS
CGC does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Canopy Growth Corporation
Sold
0-3 MONTHS
83.4 K USD 5
3-6 MONTHS
24.1 K USD 4
6-9 MONTHS
44.4 K USD 4
9-12 MONTHS
952 K USD 7
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Canopy Growth Corporation (CGC) is Attracting Investor Attention: Here is What You Should Know
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
zacks.com
- 6 days ago
Canadian Gold Corp. Private Placement Offering for New Hammond Reef South Program to Follow up 2024 Surface Samples That Returned 35.4 g/t Gold
Flin Flon, Manitoba--(Newsfile Corp. - June 19, 2025) - Canadian Gold Corp. (TSXV: CGC) ("Canadian Gold" or the "Company") is pleased to announce plans for a follow-up program on the discovery of the new high-grade zone (announced August 6, 2024), that returned 35.4 g/t and 7.1 g/t gold from surface samples at the Company's 100%-held Hammond Reef South property, located near Atikokan, Ontario. The Company's properties are adjacent to Agnico Eagle's fully permitted Hammond Reef Project, which contains a mineral resource of more than 5 million ounces of gold and occurs in the same geological environment (Fig.
newsfilecorp.com
- 1 week ago
3 Canadian Cannabis Stocks Traders Are Watching Closely This Week
Top Canadian cannabis stocks are gaining fresh attention as U.S. markets show signs of acceleration. The U.S. cannabis industry is projected to reach $45 billion by 2025. Furthermore, analysts expect it to grow past $75 billion before 2030. This momentum is driven by rising consumer demand and favorable legislative trends. Recently, federal policymakers have signaled potential changes to cannabis scheduling.
marijuanastocks.com
- 1 week ago
Canopy Growth Corporation (CGC) Stock Drops Despite Market Gains: Important Facts to Note
In the closing of the recent trading day, Canopy Growth Corporation (CGC) stood at $1.45, denoting a -2.03% move from the preceding trading day.
zacks.com
- 1 week ago
1 Beaten-Down Stock Down 99% That's Still Not Worth Buying
Canopy Growth (CGC -2.61%) emerged as a leader in the cannabis industry when Canada legalized recreational, adult use of the substance in 2018. Investors had high hopes for the company and the rest of the market but, unfortunately, these hopes have now evaporated.
fool.com
- 1 week ago
Cannabis Stock CGC Rallies 39% in Three Months: Time to Buy or Sell?
Canopy Growth surges 39% in three months as restructuring, margin gains and debt cuts renew investor interest.
zacks.com
- 1 week ago
3 Marijuana Stocks For Longterm Investors
The volatile downtrend for marijuana stocks has been both bitter and sweet. On the one hand, you have the sector trading at all-time lows. The upside to this is being able to pick up shares at a cheap price. But the sector is not as active as it once was and outside of politics, it's been challenging to find a catalyst for the sector to bounce. Nonetheless, the sweeter part is knowing that the cannabis industry becoming more successful.
marijuanastocks.com
- 2 weeks ago
Canopy Growth Corporation (CGC) Is a Trending Stock: Facts to Know Before Betting on It
Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
zacks.com
- 3 weeks ago
Shareholders of Canopy Growth Corporation Should Contact The Gross Law Firm Before June 3, 2025 to Discuss Your Rights – CGC
NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Canopy Growth Corporation (NASDAQ: CGC).
globenewswire.com
- 3 weeks ago
Lost Money on Canopy Growth Corporation (CGC)? Join Class Action Before June 3, 2025 - Contact Levi & Korsinsky
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=151506&wire=1&utm_campaign=23 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 3 weeks ago
Contact Levi & Korsinsky by June 3, 2025 to Join Class Action Against Canopy Growth Corporation (CGC)
NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Canopy Growth Corporation (NASDAQ:CGC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/canopy-growth-corporation-lawsuit-submission-form?prid=151487&wire=1&utm_campaign=10 or contact Joseph E. Levi, Esq.
accessnewswire.com
- 3 weeks ago
CGC Investors Have Opportunity to Lead Canopy Growth Corporation Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)--CGC Investors Have Opportunity to Lead Canopy Growth Corporation Securities Fraud Lawsuit with the Schall Law Firm.
businesswire.com
- 3 weeks ago
8. Profile
Summary
Canopy Growth Corporation CGC
COUNTRY
CA
INDUSTRY
Drug Manufacturers - Specialty & Generic
MARKET CAP
$ 258 M
Dividend Yield
0.00%
Description
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.
Contact
1 Hershey Drive, Smiths Falls, ON, K7A 0A8
https://www.canopygrowth.com
IPO
Date
April 7, 2014
Employees
1029
Officers
Jason Green
Head of Agriculture - Hemp Division
Mr. Andrew Bevan
Senior Vice President of Medical Sales
Mr. Jurgen Bickel
MD and Co-Founder of STORZ & BICKEL GmbH
Ms. Jenny Brewer
Chief Human Resources Officer
Mr. Luc Mongeau
Chief Executive Officer & Director
Dr. Christelle Gedeon L.L.B., Ph.D.
Chief Legal Officer & Corporate Secretary
Mr. Dave Paterson
President of Canadian Recreational Cannabis
Mr. Bryan Murphy
Senior Vice President of Operations
Mr. Tyler Burns
Director of Investor Relations
Ms. Judy Eunjoo Hong
Chief Financial Officer & Principal Accounting Officer